HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. by Tenforde, Mark W et al.
Tenforde, MW;Wake, R; Leeme, T; Jarvis, JN (2016) HIV-Associated
Cryptococcal Meningitis: Bridging the Gap Between Developed and
Resource-Limited Settings. Curr Clin Microbiol Rep, 3. pp. 92-102.
ISSN 2196-5471 DOI: 10.1007/s40588-016-0035-5
Downloaded from: http://researchonline.lshtm.ac.uk/2550587/
DOI: 10.1007/s40588-016-0035-5
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
MYCOLOGY (J PERFECT, SECTION EDITOR)
HIV-Associated Cryptococcal Meningitis: Bridging the Gap
Between Developed and Resource-Limited Settings
Mark W. Tenforde1,2 & Rae Wake3,4,5 & Tshepo Leeme6 & Joseph N. Jarvis6,7,8
Published online: 17 March 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Cryptococcal meningitis is a major cause of
HIV-associated morbidity and mortality worldwide. Most
cases occur in low-income countries, where over half of
patients die within 10 weeks of diagnosis compared to as
few as 10 % of patients from developed countries. A host
of factors, spanning the HIV care continuum, are respon-
sible for this gap in treatment outcomes between developed
and resource-limited settings. We explore factors responsi-
ble for this outcomes gap and describe low-cost, highly
effective measures that can be implemented immediately
to improve outcomes in resource-limited settings. We also
explore health-system challenges that must be addressed to
reduce mortality further, recent research in disease preven-
tion, and novel short-course treatment regimens that, if
efficacious, could be implemented in resource-limited set-
tings where the cost of standard treatment regimens is cur-
rently prohibitive.
Keywords Cryptococcal meningitis . Prevention . Health
system strengthening . Resource-limited settings
Introduction
Cryptococcal meningitis kills hundreds of thousands of peo-
ple annually, primarily HIV-infected individuals living in low-
and middle-income countries, causing up to 20 % of deaths in
HIV-infected cohorts from sub-Saharan Africa (SSA) [1•, 2,
3]. Resource-limited, high-HIV-prevalence countries not only
have a far higher incidence of cryptococcal meningitis, but
treatment outcomes are dramatically worse than in developed
countries. The reasons for these discrepancies are multifold
and span the continuum of HIV care: Lack of early HIV di-
agnosis and initiation of antiretroviral therapy (ART); low
retention in care to prevent cryptococcal disease and provide
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follow-up care after cryptococcal meningitis; poor access to
and utilization of sensitive, rapid diagnostics; inadequate ac-
cess to effective amphotericin-based treatment regimens; and
sub-optimal monitoring for and management of drug toxic-
ities, co-morbid conditions, and intracranial pressure (Table
1). Most of these factors arise directly from under-resourcing
of health care services in the face of high disease burden.
Some simple low-cost, high-impact interventions are
implementable immediately to help bridge the outcomes gap
between developed and resource-limited settings, while great-
er health system challenges to effective care will require long-
term sustained investment.
The Burden of Cryptococcal Meningitis in Developed
and Resource-Limited Settings
During the early HIV pandemic in the 1980s, cryptococcal
meningitis emerged as a major cause of mortality in HIV-
infected individuals. In the USA, Western Europe, and
Australia, cryptococcal meningitis occurred in 5–10 % of
HIV-infected individuals [4, 5]. After the rollout of ART in
the 1990s, the burden of HIV-associated disease fell dramati-
cally in high-income countries. In a study capturing hospital
data of over half of the US population, Pyrgos et al. found a
53.6 % decline in hospitalizations from HIV-associated cryp-
tococcal meningitis between 1997 and 2009, compared to a
steady rate of non-HIV-associated cryptococcal meningitis
[6•]. Similar declines were seen in France, where national
surveillance data showed a 46 % decline in the incidence of
HIV-associated cryptococcal meningitis in the early post-ART
era (1997–2001) compared to pre-ART years (1985–1996)
[7], and the UK Collaborative HIV Cohort, which showed a
15-fold decrease in the incidence of HIV-associated crypto-
coccal meningitis from 1996–1997 to 2006–2007 (from 3.0/
1000 to 0.2/1000 person-years) [8].
The vast majority of cryptococcal meningitis cases are now
seen in resource-limited countries with high HIV prevalence.
Global burden estimates of HIV-associated cryptoccoccal
meningitis, published in 2009 based on UNAIDS HIV-
prevalence estimates and studies published up to 2007, sug-
gested that of an estimated 957,900 annual cases, over 75 %
(720,000) occurred in SSAwith most of the rest in South and
Southeast Asia [1•]. The marked expansion of ART programs
in Africa and Asia since publication of these estimates has
almost certainly led to reduction in the number of cases [3],
but rates of cryptococcal meningitis remain high [3, 9].
Between November 2010 and October 2012, cryptococcal
meningitis was diagnosed in 60 % of all HIV-infected, ART-
naïve patients who received a lumbar puncture for suspected
meningitis at a tertiary care center in Uganda [10], with similar
findings published from Botswana [11], Malawi [12, 13•],
South Africa [14], Zambia [15], and Zimbabwe [16]. Pooled
estimates from studies in SSA settings published between
1987 and 2014 show cryptococcal meningitis as the
laboratory-confirmed etiology in over half of all meningitis
cases in HIV-infected patients [17].
Outcomes of Cryptococcal Meningitis in Developed
and Resource-Limited Settings
In developed countries, HIV-infected patients treated for cryp-
tococcal meningitis with standard amphotericin-based induc-
tion therapy have a mortality rate as low as 10 % at 10 weeks
in prospective randomized-controlled trials (RCTs) [18, 19].
Using more representative Busual care^ estimates, a retrospec-
tive audit of 24,151 patients hospitalized for HIV-associated
cryptococcal meningitis in the USA between 1997 and 2009
found an in-hospital mortality rate of 10.5 % (longer-term
mortality estimates were not available) [6•].
Death rates in patients treated for cryptococcal meningitis
in resource-limited settings are significantly higher than in
developed country settings. In their 2009 Global Burden of
Disease paper, Park et al. estimated 3-month HIV-associated
cryptococcal meningitis mortality at 55–70 % in low- and
middle-income settings and 70 % in SSA [1•]. This is attrib-
utable, in part, to the use of inferior fluconazole-based induc-
tion regimens in many countries. In prospective observational
studies and clinical trials, pooled 10-week mortality of HIV-
infected patients receiving high-dose fluconazole induction
therapy (800–1200 mg daily) in three Malawian studies was
Table 1 Priorities for improving HIV-associated cryptococcal menin-
gitis outcomes in resource-limited settings
Key recommendation
(1) Early HIV diagnosis and initiation of antiretroviral therapy for
primary prevention of cryptococcal meningitis
(2) Serum cryptococcal antigen (CrAg) screening of HIV-infected
patients presenting late to care (with CD4 Tcell count <100 cells/μL)
and pre-emptive antifungal therapy in asymptomatic CrAg-positive
patients
(3) Improved health facilities access to lumbar puncture supplies and
adequate health care worker training
(4) Rapid diagnostic testing for cryptococcal meningitis in meningitis
suspects with highly-sensitive point-of-care CrAg lateral flow assay
(5) Adoption of amphotericin-based induction regimens for cryptococcal
meningitis
(6) Access to affordable long-acting flucytosine for induction therapy
(7) Fluid and electrolyte replacement and monitoring during
amphotericin-based induction therapy
(8) Routine therapeutic lumbar puncture during induction therapy
(9) Diagnosis and management of common co-morbidities, e.g.,
tuberculosis and bacterial sepsis
(10) Appropriate timing of antiretroviral therapy (~5 weeks) after
cryptococcal meningitis and patient retention in care after hospital
discharge
(11) Use of maintenance fluconazole to prevent disease relapse
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56 % (70/126) and 54 % (31/57) in a prospective Ugandan
RCT [20–23] (Table 2). Even with the use of amphotericin-
based regimens, case-fatality rates in resource-limited settings
are several-fold higher than in developed country settings.
Ten-week mortality with amphotericin-based treatment regi-
mens was 33 % (13/39) in Malawi, 29 % (22/75) and 33 %
Table 2 Recent studies with early mortality estimates for cryptococcal meningitis in resource-limited settings
Country Induction regimena Mortality, % (n/N) Clinical
trial
Notes Year Ref
Botswana AmB 0.7 mg/kg daily 26 % (7/27) at 24 weeks Yes Lower mortality in group that delayed
ART for 28 days post-randomization
(15 % [2/13]) versus group that
initiated ARTwithin 7 days of
randomization (36 % [5/14])b
2013 [24]
Cameroon Regimen not specified 52 % (39/75) died in hospital No 2013 [25]
Ethiopia Mixture of AmB (n = 45) and FLU (n = 33) 48 % (37/77) died in hospital No 2012 [26]
Malawi FLU 1200 mg daily 55 % (26/47) at 10 weeks Yes 2014 [21]
Malawi FLU 800 mg daily 58 % (35/60) at 10 weeks Yes 2013 [20]
Malawi AmB 1 mg/kg daily for 7 days + FLU
1200 mg daily; AmB 1 mg/kg daily
for 7 days + 5FC 100 mg/kg daily
+ FLU 1200 mg daily
33 % (13/39) at 10 weeksb Yes Greater early fungicidal activity with
3-drug regimen
2012 [27]
Malawi FLU 1200 mg daily; FLU 1200 mg
daily + 5FC 100 mg/kg daily
50 % (20/40) at 10 weeksb Yes Greater early fungicidal activity in
combination regimen
2010 [23]
South Africa Pooled patient population from clinical trials
using AmB-based regimen
41 % (108/263) at 1 year Yes 2014 [28]
South Africa
and Uganda
AmB 0.7–1 mg/kg daily + FLU 800 mg
daily
38 % (67/177) at 26 weeks Yes Lower mortality in group that delayed
ART for 5 weeks (30 % [27/89])
versus group that started ART
1–2 weeks after diagnosis
(45 % [40/88])
2014 (43)
South Africa AmB 0.7–1 mg/kg daily +5FC 100 mg/kg
daily; AmB 0.7–1 mg/kg daily + FLU
800 mg daily; AmB 0.7–1 mg/kg
daily + FLU 600 mg daily; AmB 0.7–
1 mg/kg daily + voriconazole 300 mg
twice daily
29 % (22/75) at 10 weeksb Yes No difference in early fungicidal
activity between treatment groups
2012 [29]
South Africa Regimen not specified 89 % (66/74) at 2 years No 2011 [30]
South Africa AmB 0.7 mg/kg daily + 5FC 100 mg/kg
daily; AmB 1 mg/kg daily + 5FC
100 mg/kg daily
24 % (15/63) at 10 weeksb Yes Greater early fungicidal activity in
group receiving higher dose
of AmB
2008 [31]
South Africa AmB 1 mg/kg daily for 7 days followed
by FLU 400 mg daily
33 % (16/48) at 10 weeks No 2007 [32]
Thailand AmB 0.7 mg/kg daily; AmB 0.7 mg/kg
daily + 5FC 100 mg/kg daily; AmB
0.7 mg/kg daily + FLU 400 mg daily;
AmB 0.7 mg/kg daily + 5FC 100 mg/kg
daily + FLU 400 mg daily
22 % (14/63) at 10 weeksb Yes Greater early fungicidal activity with
combination AmB+ 5FC than
other groups
2004 [33]
Uganda AmB 1 mg/kg daily for 5 days + FLU
1200 mg daily
28 % (8/29) at 10 weeks Yes 2012 [34]
Uganda AmB 0.7–1 mg/kg daily 54 % (102/182) at 1 year No 2012 [35]
Uganda FLU 800 mg daily; FLU 1200 mg daily 54 % (31/57) at 10 weeksb Yes Greater early fungicidal activity in
group receiving higher dose of FLU
2008 [22]
Uganda AmB 0.7 mg/kg daily 59 % (26/44) at 6 months No 2008 [36]
Vietnam AmB 1 mg/kg daily for 4 weeks; AmB
1 mg/kg daily for 2 weeks + 5FC
100 mg/kg daily; AmB 1 mg/kg daily
for 2 weeks + fluconazole 400 mg daily
36 % (107/298) at 10 weeks Yes Mortality lower in combined AmB
+ 5FC group (30 % [30/100])
compared to AmB alone (44 %
[44/99])
2013 [37]
Zimbabwe Fluconazole 800 mg daily 73 % (35/48) at 3 years Yes Lower mortality in group that delayed
ART for 10 weeks after diagnosis
(54 % [12/22]) versus group that
started ARTwithin 72 h of diagnosis
(88 % [23/26])
2010 [38]
5FC flucytosine, AmB amphotericin B deoxycholate, ART antiretroviral therapy, FLU fluconazole
a Induction therapy for 14 days unless otherwise noted
bNo statistically significant difference between groups
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(16/48) in South African settings, 22 % (14/63) in Thailand,
28 % (8/29) in Uganda, and 36 % (107/298) in Vietnam
[24–29]. Long-term follow-up beyond 10 weeks shows even
higher mortality rates. Twelve-month survival in clinical trial
patients who received amphotericin-based therapy was only
59 % (155/263) in urban South Africa and 44 % (80/182) in
urban Uganda [30, 31]. Of note, most of the data above relates
to clinical trials, which select for less sick patients and provide
unrepresentative care, therefore underestimating mortality in
routine care settings. Retrospective reviews of patients treated
for HIV-associated cryptococcal meningitis in usual care set-
tings found only 48 % (36/75) of patients survived until dis-
charge at a referral center in Cameroon and 52 % (40/77) at a
referral center in Ethiopia [32, 33]. An observational cohort
study at a tertiary care center in Uganda found only 41 % (18/
44) of patients alive and receiving ART at 6 months after
cryptococcal meningitis, and a programmatic review of a dis-
trict hospital in northern Kwazulu-Natal, South Africa, found
only 11% (8/74) of patients alive and receiving ARTat 2 years
[34, 35].
Explaining the Outcomes Gap Between Resource-Rich
and Resource-Limited Settings
CD4 Counts at ARV Initiation in SSA
HIV diagnosis and ART initiation are delayed in many
resource-limited settings, particularly in sub-Saharan
Africa, increasing the risk of cryptococcal meningitis and
other HIV-associated opportunistic infections [36, 37].
Epidemiological studies from low-income countries general-
ly provide support for incremental gains in CD4 count at
ART initiation over time but also find significant heteroge-
neity between countries, and a majority of patients remain
late-presenters to care [38–40]. The International epidemio-
logical Databases to Evaluate AIDS (IeDEA) collaborative
cohort estimated a median increase in CD4 count at ART
initiation from 2002 to 2009 of 83 to 157 cells/μL in women
and 79 to 127 cells/μL in men from low-income countries
[40]. These data suggest that a large percentage of HIV-
infected individuals are at substantial risk for cryptococcal
meningitis, which typically occurs with CD4 count
<100 cells/μL [41]. In a combined cohort of patients en-
rolled in clinical studies for HIV-associated cryptococcal
meningitis in Thailand, Malawi, South Africa, and Uganda,
the median baseline CD4 count was just 24 cells/μL (IQR
10–50 cells/μL) [31], with similar CD4 counts observed in
Botswana [42], Uganda [43••], and Vietnam [29]. Very low
baseline CD4 count also increases risk for cryptococcal im-
mune reconstitution inflammatory syndrome (C-IRIS) after
the initiation of ART, characterized by an overwhelming
inflammatory response against viable or non-viable crypto-
cocci and a high mortality rate [44–46]. Thus, the high
prevalence of advanced immune suppression at presentation
to HIV-treatment programs explains not only differences in
incidence of HIV-associated meningitis between developed
and resource-limited settings but also some of the differ-
ences in disease severity and mortality rates.
For millions of people living with HIV in resource-limited
settings, the largest reduction in cryptococcal meningitis inci-
dence and mortality will be achieved through earlier HIV di-
agnosis, prompt ART initiation, and successful retention in
care. A variety of strategies have been explored to improve
HIV diagnosis, such as mobile testing and other community-
based testing strategies, home-based testing, and use of rapid
point-of-care (POC) tests [47, 48]. Strategies to improve ini-
tiation of ART and retention in care, such as health system
interventions, behavioral interventions, and financial incen-
tives, have a low supporting evidence base, and additional
effort is needed to develop and scale up strategies that are
feasible, cost-effective, and acceptable in unique local settings
[49, 50].
Diagnostic Challenges
A key factor for higher mortality rates observed in resource-
limited settings is delayed diagnosis and treatment for crypto-
coccal meningitis [51, 52]. Diagnosis may be delayed by poor
access to health care, failure of health providers to consider
cryptococcal meningitis in the differential diagnosis and
promptly initiate testing, lack of capacity to perform lumbar
puncture (LP), and/or limited availability of rapid and sensi-
tive diagnostic tests.
Diagnosis of cryptococcal meningitis relies on direct visu-
alization of encapsulated yeasts using India ink stain, culture,
or immunoassays detecting cryptococcal antigen (CrAg) in
the cerebrospinal fluid (CSF). These tests can be cost- and
labor-intensive, requiring trained laboratory personnel, equip-
ment, and availability of required reagents. This precludes
diagnosis in settings without laboratory facilities or causes a
delay while patients or samples are transferred to centers
where tests are available [53–55].
India ink stain, widely used in resource-limited settings, is
cheap and rapid but has poor sensitivity for diagnosing cryp-
tococcal meningitis [56]. Culture is a relatively cheap option,
but it also lacks sensitivity and can take several days to result
[53]. While previously available CrAg tests using latex agglu-
tination (LA) and enzyme immunoassay (EIA) require expen-
sive reagents, effective cold chains, laboratory infrastructure
and expertise, the recently developed lateral flow assay (LFA,
IMMY, Norman, OK) meets the World Health Organization
(WHO) ASSURED criteria for diagnostics in resource limited
settings (affordable, sensitive and specific, user-friendly, rapid
and robust, equipment-free, and deliverable to those who need
it) [57]. This test has the potential to revolutionize cryptococ-
cal diagnosis if made widely available. The LFA is cheap
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(retailing for just US $2 at source) and provides results within
10 min, reducing turnaround time and delays to starting anti-
fungal therapy [56, 58–62, 63••]. It can be stored at room
temperature and be performed by health workers with no lab-
oratory training, making it an ideal point-of-care test on blood
and CSF [64, 65•]. The LFA performs well in blood and CSF
samples [56, 58, 59, 62, 66, 67•, 68, 69], with a review of
published studies finding a median 100 % sensitivity and
97.7 % specificity in CSF and 100 % sensitivity and 99.5 %
specificity in serum samples [70], and has also been validated
using finger-prick capillary blood for meningitis diagnosis
[65•], although LP is still needed for pressure reduction and,
ideally, to confirm the diagnosis of central nervous system
disease.
Antifungal Treatment
Optimal antifungal regimens for cryptococcal meningitis have
been investigated in clinical trials in both developed and low-
resource settings. Recommendations rely on a relatively weak
evidence base and are tiered depending on the availability of
drugs [51]. Rapid fungal clearance from the CSF during the
initiation phase of treatment is clearly important for patient
survival [31, 71]. Amphotericin B (AmB) is highly fungicidal
and recommended as the foundation for first-line treatment
during the initial 2 weeks [51, 72]. This is based on early
clinical trial data showing superiority of AmB to fungistatic
fluconazole, particularly at higher AmB doses [25, 73, 74],
and observational and trial data showing an extremely high
mortality in patients treated with fluconazole monotherapy,
even at very high doses [20–23].
Flucytosine further increases the rate of fungal clearance
when used with AmB induction therapy [24, 28, 75]. A ran-
domized trial in Vietnam demonstrated a significant mortality
benefit when flucytosine was used in combination with AmB
(1 mg/kg daily) compared to AmB alone in 298 HIV-positive
patients (hazard ratio [HR] 0.61, 95 % CI 0.39–0.97) [29].
Due to a lack of flucytosine in most resource-limited settings,
when AmB is used, it is usually given in combination with
fluconazole. Evidence to inform the optimal dosing of flucon-
azole is lacking with no confirmed mortality benefit, although
the addition of fluconazole to AmB has a favorable effect on
early fungal clearance [24, 26, 76, 77].
Despite the survival benefit with the use of amphotericin
and flucytosine, the cost, availability, and health system re-
quirements for administering these drugs are prohibitive in
most settings where cryptococcal meningitis remains a major
cause of death [78]. This continues to be the case despite the
inclusion of both AmB and flucytosine on to the WHO list of
Essential Medicines in 2013 [79]. Taking into account drug,
laboratory, and personnel costs as well as hospital supplies,
the cost of first-line 14-day induction therapy with AmB and
flucytosine was estimated at US $467.48 per patient in 2012
[80••]. This is unaffordable in a majority of settings despite the
fact that this estimate was based on an international wholesale
price of flucytosine [78]. A combination of high costs, low
demand, and concerns regarding toxicity mean that
flucytosine remains unregistered across most of Asia and in
all countries in Africa [78].
Aside from cost and availability, toxicities associated
with amphotericin and flucytosine, along with the require-
ment for IV administration of amphotericin, may partly
explain the ongoing reliance on fluconazole monotherapy
for cryptococcal meningitis in resource-limited settings
[81]. Lack of resources to manage drug-related complica-
tions and problems related to prolonged hospitalization
may also contribute to the persistently higher mortality
compared to resource-rich settings [24, 26, 29, 74].
Lipid-based amphotericin formulations are less toxic but
are currently unaffordable in most low- and middle-
income country settings [78]. However, pre-emptive fluid
and electrolyte replacement can reduce the risk of nephro-
toxicity with amphotericin, an approach recommended in
WHO guidelines for the management of cryptococcal men-
ingitis [51, 82•]. A prospective cohort study conducted in
Uganda observed an improvement in 14-day survival from 49
to 62 % (p=0.003) with the introduction of universal admin-
istration of 1 L of IV normal saline prior to amphotericin [82•].
Concerns regarding bone marrow toxicity with flucytosine
have diminished with clinical trials showing that a lower dose
of 100 mg/kg daily is safe and effective and without a need to
check therapeutic drug levels as long as complete blood
counts are monitored [24, 29].
Shorter courses of amphotericin induction therapy or
fully oral regimens with high-dose fluconazole and
flucytosine may offer alternative solutions to the current
tiered recommendations [23, 27, 28]. A recent analysis
concluded that an induction course of AmB (1 mg/kg dai-
ly) for 5–7 days and fluconazole 1200 mg daily for 14 days
was the most cost-effective regimen compared to flucona-
zole alone, fluconazole, and flucytosine, and currently rec-
ommended first-line therapy of AmB and flucytosine. This
regimen provided an additional 4.2 quality adjusted life
years (QALYs) at an incremental cost of US $15.11/addi-
tional QALY. A 14-day course of flucytosine and flucona-
zole (1200 mg daily) was the next most cost-effective reg-
imen [80••]. An ongoing phase III randomized controlled
trial (Advancing Crytococcal meningitis Treatment in
Africa, ACTA, ISRCTN45035509) [46] will verify if these
simpler regimens could improve the currently unacceptable
levels of cryptococcal-associated mortality [83]. The ongo-
ing phase II trial, AMBITION-cm (ISRCTN10248064), is
also evaluating the safety and early fungicidal activity of
high-dose liposomal amphotericin (AmBisome) at even
shorter courses (as little as 1 dose at 10 mg/kg) with flu-
conazole 1200 mg daily for 14 days [84].
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Therapeutic Lumbar Punctures
Raised intracranial pressure (ICP) in cryptococcal meningitis
is caused by obstruction to CSF reabsorption at the arachnoid
granulations, likely secondary to accumulation of cryptococci
and shed capsular polysaccharides, and associated with higher
fungal burden [85]. Increased baseline ICP and persistently
elevated ICP are associated with neurological sequelae and
mortality [86, 87]. The introduction of routine ICP measure-
ment on days 3, 7, and 14, and daily therapeutic LPs until ICP
was ≤20 cm H2O, for all cases of cryptococcal meningitis in a
Tanzanian hospital was associated with a 30-day mortality
reduction from 76 to 46 % (HR 2.1, 95 % CI 1.1–3.8) [88].
In addition to decreasing intracranial pressure, lumbar punc-
ture reduces the concentration of capsular polysaccharide
(CrAg), potentially providing additional benefit through re-
duction in cryptococcus and/or shed capsular components
[89]. Even after adjusting for baseline CSF opening pressure,
at least one therapeutic LP after initial diagnostic LP was
associated with a 69 % (95 % CI 18–88 %) improvement in
survival compared to no LP in a cohort of 248 patients with
HIV-associated cryptococcal meningitis in Uganda and South
Africa [90••].
Despite this evidence for the benefit of intensive ICP man-
agement, it is often poorly adhered to in resource-limited set-
tings due to lack of equipment and trained personnel, and a
poor level of acceptance by patients [34, 88, 91]. Routine
scheduling of lumbar punctures during the first 2 weeks of
treatment regardless of ICP measurements, as will be included
in updated WHO guidelines, will simplify management of
raised intracranial pressure and hopefully lead to improved
implementation in resource-limited settings. And readily
available IV tubing can be used to accurately measure and
manage intracranial pressure where the lack of manometers
impedes the implementation of serial lumbar punctures [88].
However, efforts must still be made to further understand and
address the personal or cultural barriers that inhibit patients
from consenting to having LPs in order to improve adherence
to this important intervention [91].
Post-discharge and Long-Term Management
The early post-hospitalization period is a critical time for pa-
tients who have received induction therapy for cryptococcal
meningitis. About half of deaths within the first 10 weeks of
cryptococcal meningitis diagnosis occur within the first
2 weeks and are primarily related to cryptococcal disease
[31]; the remaining deaths in the ensuing weeks are often
due to other HIV-associated infections and complications as
well as cryptococcal immune reconstitution inflammatory
syndrome, highlighting the need for close follow-up and high
clinical vigilance. After induction therapy for cryptococcal
meningitis with an AmB-based regimen, the COAT trial
recently demonstrated a significant 26-week mortality benefit
of delayed ART at 5 weeks rather than 1–2 weeks after diag-
nosis (HR for death 1.73 95 % CI 1.06–2.82) [43••].
Appropriate timing of ART in routine care settings will require
careful coordination to prevent both death from premature
ART initiation and risk of meningitis relapse or other compli-
cations with excessive delay in starting ART. In settings that
rely on fluconazole-based induction therapy, early ART is
clearly harmful although optimal timing is not clearly
established [92].
Many patients with cryptococcal meningitis in resource-
limited settings never return to health facilities to receive
ARTor continuation of maintenance fluconazole therapy (rec-
ommended for secondary prevention of cryptococcal menin-
gitis) after they are discharged from the hospital. A retrospec-
tive case series in KwaZulu-Natal, South Africa, found that
only 9/44 (20 %) of patients collected maintenance phase
fluconazole and 11 % (95 % CI 8.7–12.8) were known to be
alive and receiving ART after 2 years [35]. In a cohort of
patients presenting with recurrent cryptococcal meningitis in
South Africa, 30/69 (43 %) were not taking secondary pro-
phylaxis and 8 (12 %) had not commenced ART [93•]. Poor
adherence to maintenance fluconazole therapy and low levels
of ART initiation lead to a high rate of relapse, which urgently
needs addressing in resource-limited settings.
Prevention of Cryptococcal Meningitis Through CrAg
Screening
CrAg testing can be performed on blood samples to screen for
patients with early asymptomatic disease who are at a risk of
cryptococcal meningitis. Cryptococcal antigenemia is strong-
ly predictive of the development of cryptococcal meningitis in
patients with late-stage HIV infection enrolling for ART
[94–96]. A Bscreen-and-treat^ strategy for preventing crypto-
coccal meningitis was conditionally recommended by the
WHO in 2011 based on modeling showing that pre-emptive
antifungal therapy, if effective in the prevention of down-
stream clinical disease, is a highly cost-effective strategy
[51, 97, 98]. The WHO guidelines recommend that HIV-
infected adults with CD4 counts <100 cells/μL and CrAg
detected in serum or plasma receive a tapered course of flu-
conazole (800mg daily for 2 weeks, followed by 400mg daily
for 8 weeks and then 200 mg daily pending immune reconsti-
tution) as long as they have no signs or symptoms of menin-
gitis (in which case they should receive a lumbar puncture to
evaluate for meningitis). This approach has been introduced in
a number of developing country settings, and prospective ev-
idence now shows it to be efficacious in reducing the inci-
dence and mortality associated with cryptococcal meningitis
[99, 100••, 101, 102]. Several large-scale implementation
studies, including the Operational Research for Cryptococcal
An t i g en Sc r e en i ng (ORCAS) t r i a l i n Uganda
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(NCT01535469), are underway to guide implementation of
screening in resource-limited settings [103].
Conclusions—Closing the Outcomes Gap
In contrast to the 1980s and 1990s, clinical trials for crypto-
coccal meningitis are now almost exclusively conducted in
resource-limited settings. These studies improve our under-
standing of disease and guide management in resource-poor
and resource-rich settings alike [72, 104]. It is imperative,
therefore, that not only is cryptococcal meningitis research
further expanded in resource-limited settings to provide better
prevention and treatment strategies, but that findings from
these studies are translated into widespread clinical practice
to achieve better outcomes in those regions most affected by
this disease.
Studies in the past 5 years demonstrate that several relative-
ly cheap and feasible measures can be implemented that
would have a sizable impact on cryptococcal meningitis out-
comes. These include cryptococcal antigen screening in vul-
nerable patients initiating ART; earlier cryptococcal diagnosis
through adoption of the point-of-care CrAg lateral flow assay,
which is highly sensitive and also cheaper than traditional
assays; reliable availability of LP supplies and performance
of therapeutic LP as a routine part of care; improved access to
AmB and flucytosine; and use of routine IV fluid and electro-
lytes in patients receiving amphotericin-based treatment.
These measures require strengthened health systems with
steady supply chains, improved training of front-line health
workers, and efforts to understand barriers and improve pa-
tient acceptance of LP.
Amphotericin is the backbone of effective treatment for
cryptococcal meningitis, and efforts must be made to increase
availability in all settings, particularly as high-dose flucona-
zole has now been shown to be associated with unacceptably
poor outcomes (>50 % mortality within 10 weeks of diagno-
sis). Several phase II and phase III trials are currently under-
way to evaluate the efficacy of shortened courses of
amphotericin-based regimens. If shown to be safe and effica-
cious, such short course induction could significantly reduce
in-hospital time and total costs of treatment and facilitate
greater adoption of amphotericin-based treatment in
resource-limited settings.
Finally, HIV care is moving increasingly toward a test-and-
treat approach given strong evidence for improved long-term
patient outcomes and the clear value of HIV treatment as
prevention (TasP) [105]. Adoption of earlier diagnosis and
ART initiation should ultimately make cryptococcal meningi-
tis a rare disease. This will require not only financial buy-in
but also significant investment in operational and implemen-
tation strategies to reach vulnerable populations, many of
whom are already being missed by current ART programs,
and maintain lifelong ART uptake for prevention of
cryptococcal meningitis and other HIV-associated diseases.
Significant efforts will also be needed to improve coordination
of care if CrAg screening for prevention of cryptococcal men-
ingitis is going to be more widely adopted and effective, as
well as to prevent loss to follow-up in patients who receive
hospital care for incident cryptococcal meningitis. Using the
tools we already have, it is possible to make considerable
gains in closing the gap in both incidence and outcomes be-
tween developed and resource-limited settings for this devas-
tating disease.
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